LpxC inhibitors: a patent review (2010-2016)

References

• The top 10 causes of death. Fact sheet No. 310 [internet]. Geneva: World Health Organization; 2017. cited 2017 July 29. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Perman SM, Goyal M, Gaieski DF. Initial emergency department diagnosis and management of adult patients with severe sepsis and septic shock. Scand J Trauma Resusc Emerg Med. 2012;20:41.
   PubMed Web of Science ®Google Scholar
• Slade E, Tamber PS, Vincent JL. The surviving sepsis campaign: raising awareness to reduce mortality. Crit Care. 2003;7(1):1–2.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529–539.
   PubMed Web of Science ®Google Scholar
• Arias CA. Murray BE: the rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266–278.
   PubMed Web of Science ®Google Scholar
• Stefani S, Chung DR, Lindsay JA, et al. Methicillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents. 2012;39(4):273–282.
   PubMed Web of Science ®Google Scholar
• Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics [internet]. 2017 cited 2017 Mar 20. Available from: http://www.Who.Int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Press Release.
   Google Scholar
• Guentzel MN. Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus. In: Baron S, editor. Medical microbiology. University of Texas Medical Branch at Galveston, Galveston (TX); 1996.
   Google Scholar
• Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 2006;34(5 Suppl 1): S20–28. discussion S64-73.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Ginocchio F, Mikulska M, et al. Will new antimicrobials overcome resistance among gram-negatives? Expert Rev Anti Infect Ther. 2011;9(10):909–922.
   PubMed Web of Science ®Google Scholar
• Peleg AY. Hooper DC: hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804–1813.
   PubMed Web of Science ®Google Scholar
• Wright GD. Aminoglycoside-modifying enzymes. Curr Opin Microbiol. 1999;2(5):499–503.
   PubMed Web of Science ®Google Scholar
• Silhavy TJ, Kahne D. Walker S: the bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010;2(5):a000414.
   PubMed Web of Science ®Google Scholar
• Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794(5):808–816.
   PubMed Web of Science ®Google Scholar
• Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob Agents Chemother. 1993;37(2):354–356.
   PubMed Web of Science ®Google Scholar
• Vuorio R, Vaara M. The lipid A biosynthesis mutation lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob Agents Chemother. 1992;36(4):826–829.
   PubMed Web of Science ®Google Scholar
• Lerouge I, Vanderleyden J. O-antigen structural variation: mechanisms and possible roles in animal/plant-microbe interactions. FEMS Microbiol Rev. 2002;26(1):17–47.
   PubMed Web of Science ®Google Scholar
• Raetz CR, Reynolds CM, Trent MS, et al. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem. 2007;76:295–329.
   PubMed Web of Science ®Google Scholar
• Kalinin DV, Holl R. Insights into the zinc-dependent deacetylase LpxC: biochemical properties and inhibitor design. Curr Top Med Chem. 2016;16(21):2379–2430.
   PubMed Web of Science ®Google Scholar
• Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635–700.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Rusche KM, Shin H, et al. Christianson DW: crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc Natl Acad Sci USA. 2003;100(14):8146–8150.
   PubMed Web of Science ®Google Scholar
• Clayton GM, Klein DJ, Rickert KW, et al. Structure of the bacterial deacetylase LpxC bound to the nucleotide reaction product reveals mechanisms of oxyanion stabilization and proton transfer. J Biol Chem. 2013;288(47):34073–34080.
   PubMed Web of Science ®Google Scholar
• Barb AW, McClerren AL, Snehelatha K, et al. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry. 2007;46(12):3793–3802.
   PubMed Web of Science ®Google Scholar
• Barb AW, Jiang L, Raetz CR, et al. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci USA. 2007;104(47):18433–18438.
   PubMed Web of Science ®Google Scholar
• Reddy PAP, Mansoor UF, Siddiqui MA, Merck Sharp & Dohme Corp. Synthesis and use of heterocyclic antibacterial agents. WO 2009158369. 2009.
   Google Scholar
• Brown MF, Reilly U, Abramite JA, et al. Potent inhibitors of LpxC for the treatment of gram-negative infections. J Med Chem. 2012;55(2):914–923.
   PubMed Web of Science ®Google Scholar
• Montgomery JI, Brown MF, Reilly U, et al. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J Med Chem. 2012;55(4):1662–1670.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Liang X, Chen X, et al. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. Chem Biol. 2011;18(1):38–47.
   PubMed Web of Science ®Google Scholar
• Liang X, Lee CJ, Chen X, et al. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold. Bioorg Med Chem. 2011;19(2):852–860.
   PubMed Web of Science ®Google Scholar
• Liang X, Lee CJ, Zhao J, et al. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors. J Med Chem. 2013;56(17):6954–6966.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Liang X, Wu Q, et al. Drug design from the cryptic inhibitor envelope. Nat Commun. 2016;7:10638.
   PubMed Web of Science ®Google Scholar
• Mansoor UF, Vitharana D, Reddy PA, et al. Siddiqui MA: design and synthesis of potent gram-negative specific LpxC inhibitors. Bioorg Med Chem Lett. 2011;21(4):1155–1161.
   PubMed Web of Science ®Google Scholar
• Mansoor UF, Reddy PA, Siddiqui MA, Schering Corporation, USA. Preparation of urea derivatives as antibacterial agents for treatment of diseases mediated by LpxC. WO 2010017060. 2010.
   Google Scholar
• Patten PA, Armstrong ES, Achaogen, Inc., USA. Combinations comprising a LpxC inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria. WO 2011005355. 2011.
   Google Scholar
• Kasar R, Linsell MS, Aggen JB, et al., Achaogen, Inc., USA. Preparation of hydroxamic acid derivatives useful in the treatment of bacterial infections. WO 2012154204. 2012.
   Google Scholar
• Serio AW, Kubo A, Lopez S, et al. Structure, potency and bactericidal activity of ACHN-975, a first-in-class LpxC inhibitor. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, Colorado, United States; September 10-13, 2013, poster # F-1226. Available from: https://static1.squarespace.com/static/51199d96e4b084d1d0b105c3/t/526eb044e4b043e300352a3f/1382985796744/ICAAC-2013_Poster_F-1226.pdf.
   Google Scholar
• Badal R, Hoban D, Hackel M, et al. In vitro activity of ACHN-975 against 1,050 non-fermentative gram-negative bacilli. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, Colorado, United States; September 10-13, 2013, poster # E-614. Available from: https://static1.squarespace.com/static/51199d96e4b084d1d0b105c3/t/52702f8de4b03475d0db8b76/1383083917349/ICAAC-2013_Poster_E-614.pdf.
   Google Scholar
• Marchand C, Miller L, Halasohoris S, et al. In vitro activity of ACHN-975 against biodefense pathogens. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, Colorado, United States; September 10-13, 2013, poster # E-1187. Available from: https://static1.squarespace.com/static/51199d96e4b084d1d0b105c3/t/52701ea0e4b0d777ef6203c8/1383079584922/ICAAC-2013_Poster_E-1187.pdf.
   Google Scholar
• Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54(12):4971–4977.
   PubMed Web of Science ®Google Scholar
• Trend R, Kasar RA, Achaogen, Inc., USA. Preparation of N-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide useful in the treatment of bacterial infection. WO 2013039947. 2013.
   Google Scholar
• Achaogen Inc. Annual report on form 10-k. 2015. Available from: http://investors.Achaogen.Com/secfiling.Cfm?Filingid=1628280-15-1797&cik=:
   Google Scholar
• Achaogen, Inc. A study to assess the safety, tolerability, and pharmacokinetics of ACHN-975 in healthy volunteers. In: clinicaltrials.Gov [internet]. Bethesda (MD): National library of medicine (US); 2000. cited 2016 Mar 09. Available from: https://clinicaltrials.Gov/ct2/show/nct01597947?Term=nct01597947&rank=1 Nlm identifier: Nct01597947:.
   Google Scholar
• Achaogen, Inc. A multiple dose study to assess the safety, tolerability, and pharmacokinetics of ACHN-975 in healthy volunteers. In: Clinicaltrials.Gov [internet]. Bethesda (MD): National library of medicine (US); 2000. cited 2016 Mar 09. Available from: https://clinicaltrials.Gov/ct2/show/nct01870245?Term=achn-975&rank=1 Nlm identifier: Nct01870245:.
   Google Scholar
• Singh SB. Confronting the challenges of discovery of novel antibacterial agents. Bioorg Med Chem Lett. 2014;24(16):3683–3689.
   PubMed Web of Science ®Google Scholar
• Linsell MS, Aggen JB, Dozzo P, et al., Achaogen, Inc., USA. Preparation of phenyl azetidinyl and phenyl pyrrolidinyl compounds as antibacterial agents that act by inhibiting LpxC. WO 2014165075. 2014.
   Google Scholar
• Benenato KE, Choy AL, Hale MR, et al., AstraZeneca AB, Swed.; AstraZeneca UK Limited. Preparation of hydroxamic acid derivatives as gram-negative antibacterial agents. WO 2010100475. 2010.
   Google Scholar
• Brown MF, Marfat A, Melnick MJ, et al., Pfizer Inc., USA. Preparation of C-linked hydroxamic acid derivatives as antibacterial agents. WO 2011045703. 2011.
   Google Scholar
• Brown MF, Che Y, Marfat A, et al., Pfizer Inc., USA. N-linked hydroxamic acid derivatives as antibacterial agents and their preparation and use in the treatment of bacterial infection. WO 2011073845. 2011.
   Google Scholar
• Brown MF, Che Y, Melnick MJ, et al., Pfizer Inc., USA. Preparation of fluoro-pyridinone methylsulfonyl hydroxamate derivatives as antibacterial agents. WO 2012120397. 2012.
   Google Scholar
• Abramite JA, Brown MF, Chen JM, et al., Pfizer Inc., USA. Preparation of isoxazole derivatives useful as antibacterial agents. WO 2012137094. 2012.
   Google Scholar
• Brown MF, Chen JM, Melnick M, et al., Pfizer Inc., USA. Preparation of N-linked hydroxamic acid derivatives as LpxC inhibitors useful as antibacterial agents. WO 2012137099. 2012.
   Google Scholar
• McAllister LA, Montgomery JI, Abramite JA, et al. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as gram-negative antibacterial agents. Bioorg Med Chem Lett. 2012;22(22):6832–6838.
   PubMed Web of Science ®Google Scholar
• Chapoux G, Gauvin J-C, Panchaud P, et al., Actelion Pharmaceuticals Ltd., Switz. Preparation of dihydropyrrolo[1,2-c]imidazol-3-one derivatives useful as antibacterial agents. WO 2015132228. 2015.
   Google Scholar
• Gauvin J-C, Surivet J-P, Actelion Pharmaceuticals Ltd., Switz. Preparation of antibacterial quinazoline-4(3H)-one derivatives. WO 2015173329. 2015.
   Google Scholar
• Dobler MR, Lenoir F, Parker DT, et al., Novartis AG, Switz. Preparation of ((hydroxyamino)oxoethyl)benzamide derivatives for use as antibacterial agents. WO 2010031750. 2010.
   Google Scholar
• Fu J, Karur S, Madera AM, et al., Novartis AG, Switz. Preparation of hydroxamic acid derivatives as LpxC inhibitors useful for the treatment of bacterial infection. WO 2014160649. 2014.
   Google Scholar
• Fu J, Karur S, Lee P, et al., Novartis AG, Switz.; Jin, Xianming; Lapointe, Guillaume. Preparation of isoxazoline hydroxamic acid derivatives as LpxC inhibitors useful for the treatment of bacterial infection. WO 2015164458. 2015.
   Google Scholar
• Fu J, Lee P, Madera AM, et al., Novartis AG, Switz. Preparation of oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections. WO 2015066413. 2015.
   Google Scholar
• Zhou P, Toone EJ, Duke University, USA Ethynylbenzene derivatives as LpxC inhibitors and their preparation and use for the treatment of gram-negative bacterial infections. WO 2012031298. 2012.
   Google Scholar
• Zhou P, Toone EJ, Nicholas RA, Duke University, USA Substituted hydroxamic acid compounds. WO 2015024010. 2015.
   Google Scholar
• Zhou P, Toone EJ, Nicholas RA, Duke University, USA. Gram-negative antibacterial compounds. WO 2015024021. 2015.
   Google Scholar
• Zhou P, Toone EJ, Nicholas RA, Duke University, USA. 2-Piperidinyl N,3-dihydroxybutanamide as antibacterial agents. WO 2015024016. 2015.
   Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233–241.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. Pazdur R: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–1252.
   PubMed Web of Science ®Google Scholar
• Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood. 2009;114(22):379–379.
   Web of Science ®Google Scholar
• Dalvie D, Cosker T, Boyden T, et al. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans. Drug Metab Dispos. 2008;36(9):1869–1883.
   PubMed Web of Science ®Google Scholar
• Mulder GJ. Meerman JHN: sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids – the role of N,O-sulfonation in chemical carcinogenesis of aromatic-amines. Environ Health Persp. 1983;49:(Mar):27-32.
   PubMed Web of Science ®Google Scholar
• Warmus JS, Quinn CL, Taylor C, et al. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC. Bioorg Med Chem Lett. 2012;22(7):2536–2543.
   PubMed Web of Science ®Google Scholar
• Whittaker M, Cd F, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99(9):2735–2776.
   PubMed Web of Science ®Google Scholar
• Chen MH, Steiner MG, De Laszlo SE, et al. Raetz CRH: carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis. Bioorg Med Chem Lett. 1999;9(3):313–318.
   PubMed Web of Science ®Google Scholar
• Cuny GD. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of gram-negative infections: PCT application WO 2008027466. Expert Opin Ther Pat. 2009;19(6):893–899.
   PubMed Web of Science ®Google Scholar
• Jackman JE, Fierke CA, Tumey LN, et al. Raetz CRH: antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(R-3-hydroxymyristoyl)-N-acetyglucosamine deacetylases by substrate analogs containing zinc binding motifs. J Biol Chem. 2000;275(15):11002–11009.
   PubMed Web of Science ®Google Scholar
• Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit lipid A biosynthesis. Science. 1996;274(5289):980–982.
   PubMed Web of Science ®Google Scholar
• Pirrung MC, Tumey LN, Raetz CRH, et al. Rusche KM: inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups. J Med Chem. 2002;45(19):4359–4370.
   PubMed Web of Science ®Google Scholar
• Shin H, Gennadios HA, Whittington DA, et al. Amphipathic benzoic acid derivatives: synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC. Bioorg Med Chem. 2007;15(7):2617–2623.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Puerta DT, Perez C, The Regents of the University of California, USA. Inhibitors of LpxC. WO 2015085238. 2015.
   Google Scholar
• Hoekstra WJ, Yates CM, Rafferty SW, Viamet Pharmaceuticals, Inc., USA. Preparation of naphthyridine and isoquinoline derivatives as metalloenzyme inhibitors. WO 2014117090. 2014.
   Google Scholar
• Achaogen Inc.: Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 [internet]. 2017 cited 2017 Jul 10. Available from: http://investors.Achaogen.Com/secfiling.Cfm?Filingid=1564590-17-4283&cik=1301501
   Google Scholar
• Zeng D, Zhao J, Chung HS, et al. Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis. J Biol Chem. 2013;288(8):5475–5486.
   PubMed Web of Science ®Google Scholar
• Tomaras AP, McPherson CJ, Kuhn M, et al. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in gram-negative pathogens. MBio. 2014;5(5):e01551–01514.
   PubMed Web of Science ®Google Scholar
• Caughlan RE, Jones AK, Delucia AM, et al. Dean CR: mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(1):17–27.
   PubMed Web of Science ®Google Scholar
• Clements JM, Coignard F, Johnson I, et al. Hunter MG: antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother. 2002;46(6):1793–1799.
   PubMed Web of Science ®Google Scholar
• Boll JM, Crofts AA, Peters K, et al. Trent MS: A penicillin-binding protein inhibits selection of colistin-resistant, lipooligosaccharide-deficient Acinetobacter baumannii. Proc Natl Acad Sci USA. 2016;113(41). E6228-E6237.
   Web of Science ®Google Scholar
• Lin L, Tan B, Pantapalangkoor P, et al. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio. 2012;3:5.
   Web of Science ®Google Scholar